Pharma major Dr Reddy's Laboratories Ltd has propelled Invista. It is a detailing of Dasatinib that is bioequivalent to the pioneer brand.

Patent on Dasatinib is possessed by <span style="color: #ff6600;"><a style="color: #ff6600;" href="https://www.bms.com/">Bristol-Myers-Squibb</a></span>. The Indian patent has lapsed on April 12, 2020.

It is demonstrated for the treatment of ceaseless quickened or myeloid or lymphoid impact stage and recently analyzed in interminable stage grown-up patients with Chronic Myeloid Leukemia (CML) in India.

"The improvement and dispatch of Invista is a critical advance forward in improving access to drugs at a reasonable cost for CML patients in India," <span style="color: #ff6600;"><a style="color: #ff6600;" href="https://www.reuters.com/companies/REDY.BO">M V Ramana, Chief Executive Office</a></span>r, Branded Markets (India and Emerging Markets), Dr Reddy's Laboratories said in a discharge on Monday.

Hyderabad - based Dr Reddy's Invista is accessible in qualities of 50, 70 and 100 mg